Keyes Jason A purchased $11K of BLSM
Keyes Jason A (Chief Financial Officer) purchased 700 shares of BlossomHill Therapeutics, Inc. (BLSM) at $16.00 on 2026-08-10.
How this was made
The 30-second read
Why it matters
A CFO open-market purchase may provide a small sentiment tailwind, but the disclosure does not include new company performance, guidance, or regulatory/clinical catalysts.
Market read
Traders may note the insider buy for sentiment, but the transaction is small and not a fundamental catalyst.
What to watch
No 10b5-1 plan is cited, but the filing still lacks context on motivation, timing constraints, or whether the purchase is part of a broader compensation or liquidity pattern.
Background
This is an SEC Form 4 insider transaction disclosure for BlossomHill Therapeutics, Inc.
Ticker impact
BlossomHill Therapeutics CFO Jason Keyes filed a Form 4 for an open-market purchase of 700 shares at $16.00 on 2026-08-10.
Low likelihood of a sustained move; any reaction is likely limited and short-lived unless accompanied by other company-specific news.
Form 4 insider purchases can support sentiment, but this transaction size ($11.2k) is small and provides no new operational or financial guidance.
Market effects
No clear sector read-through from a small, routine insider purchase.
None indicated.
None indicated.
Counterpoint
Insider buys on Form 4 can be routine or opportunistic and do not necessarily signal improved fundamentals, especially at small dollar amounts.
Key entities
- issuerBlossomHill Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderJason Keyes
Chief Financial Officer who purchased 700 shares open-market at $16.00 on 2026-08-10.
